Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) EBT Margin (2017 - 2025)

Historic EBT Margin for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to 90972.73%.

  • Crinetics Pharmaceuticals' EBT Margin changed N/A to 90972.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 27537.2%, marking a year-over-year decrease of 12604900.0%. This contributed to the annual value of 28625.51% for FY2024, which is 234131500.0% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' EBT Margin is 90972.73%.
  • Crinetics Pharmaceuticals' EBT Margin's 5-year high stood at 1074.23% during Q1 2022, with a 5-year trough of 90972.73% in Q3 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' median EBT Margin value was 9641.23% (recorded in 2022), while the average stood at 16168.04%.
  • The largest annual percentage gain for Crinetics Pharmaceuticals' EBT Margin in the last 5 years was 73389500bps (2025), contrasted with its biggest fall of -164058100bps (2025).
  • Over the past 5 years, Crinetics Pharmaceuticals' EBT Margin (Quarter) stood at 2857.88% in 2021, then crashed by -125bps to 6438.93% in 2022, then tumbled by -153bps to 16302.89% in 2023, then decreased by -14bps to 18556.89% in 2024, then plummeted by -390bps to 90972.73% in 2025.
  • Its last three reported values are 90972.73% in Q3 2025, 11217.94% for Q2 2025, and 26750.97% during Q1 2025.